Group items tagged

Forensic pathology is the application of clinical medical jurisprudence in forensic medicine. A forensic pathology specialist is a physician who has completed a residency in molecular biology, pathology, and related disciplines and has then specialized in forensic pathology as a post-graduate program. The standards for being a "fully certified" forensic pathology specialist vary from state to state. There are also national accreditation programs that offer associates or bachelor's degrees for forensic pathology specialists. Forensic pathology can be applied to a wide range of situations, such as drug and alcohol abuse, homicide and other crimes, sexual assault, and sexual motivation. Forensic pathology specialists can analyze tissue samples to examine for disease, and they use various methods to determine the cause of death, cause of trauma, etc. For instance, gas chromatography is used in the forensic pathology for analyzing fibers on the body. Moreover it also used to analyze blood found at a crime scene. There are many types of forensic pathology, and each type involves different techniques and terminology. Some examples include: pathology of blood and other bodily fluids; pathology of sexually transmitted diseases; pathology of trauma; pathology of forensic genitourinary and obstetric disorders; pathology of traumatic and infectious diseases; pathology of unidentified remains. Read More @ https://www.blogger.com/blog/post/edit/preview/9197580861156902959/6381348933167984177

Protein A colorimetric resins are the most extensively used affinity purifiers in bio-manufacturing and other industries. Protein A colorimetry is a robust, high-throughput chromatography method and is used primarily as a capture step because of its inherent precision. Approval and launch of new biosimilars is expected to propel growth of the protein A resin market. For instance, in December 2020, Sandoz Canada Inc., a generics and biosimilars manufacturer and a division of the Switzerland-based multinational Novartis AG, received Health Canada authorization for Hyrimoz (adalimumab injection, reference biologic drug: Humira) on November 4, 2020 for marketing in Canada. Hyrimoz, the new biosimilar, has been approved for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis. Moreover, high prevalence of chronic diseases is also expected to aid in growth of the protein A resin market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/emergence-of-covid-19-to-offer_23.html